55279-29-3

Basic information

• Product Name: 3-AMINO-PYRIDINE-4-CARBALDEHYDE
• Synonyms: 3-AMINO-PYRIDINE-4-CARBALDEHYDE;3-AMINOPYRIDINE-4-CARBOXALDEHYDE;3-AMINOISONICOTINALDEHYDE;3-AMINO-4-PYRIDINECARBOXALDEHYDE;3-AMINO-4-CARBOXALDEHYDE;3-Aminopyridine-4-carboxaldehyde 97%;3-AMINO-PYRIDINE-4-C;3-Aminoisonicotinaldehyde 97%
• CAS NO: 55279-29-3
• Molecular Formula: C₆H₆N₂O
• Molecular Weight: 122.12
• Product Categories: Pyridine series;Aldehydes;Pyridines;Amines;Aromatics;Heterocycles;Intermediates;Heterocycle-Pyridine series
• Mol File: 55279-29-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: ca 92℃
• Boiling Point: 333.3 °C at 760 mmHg
• Flash Point: 155.4 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 0.000138mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.19±0.18(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-AMINO-PYRIDINE-4-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-PYRIDINE-4-CARBALDEHYDE(55279-29-3)
• EPA Substance Registry System: 3-AMINO-PYRIDINE-4-CARBALDEHYDE(55279-29-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 55279-29-3(Hazardous Substances Data)

Usage

Description

3-Amino-pyridine-4-carbaldehyde is an organic compound with the molecular formula C6H6N2O. It is a derivative of pyridine, featuring an amino group and a formyl group attached to the pyridine ring. 3-AMINO-PYRIDINE-4-CARBALDEHYDE is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical structure and reactivity.

Uses

Used in Pharmaceutical Industry:
3-Amino-pyridine-4-carbaldehyde is used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its presence in the molecular structure can contribute to the biological activity and therapeutic effects of the final drug product.
Used in the Synthesis of Hydroxyquinolin-2(1H)-ones:
3-Amino-pyridine-4-carbaldehyde is used in the preparation of hydroxyquinolin-2(1H)-ones and their derivatives. These compounds have potential applications in treating cognitive-related disorders and neuropathic pain disorders. The unique chemical structure of 3-amino-pyridine-4-carbaldehyde allows for the development of novel therapeutic agents that can target specific neurological conditions.

InChI:InChI=1/C6H6N2O/c7-6-3-8-2-1-5(6)4-9/h1-4H,7H2

Upstream product

• 152398-05-5 (3-amino-pyridin-4-yl)methanol 
• 116026-95-0 3--4-pyridinecarboxaldehyde 
• 4664-01-1 3,4-pyridinedicarboximide 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 14208-83-4 ethyl 3-aminopyridine-4-carboxylate 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 1352037-93-4 N-methoxy-N-methyl 3-amino-isonicotinamide 
• 55279-30-6 methyl 3-aminoisonicotinate 
• 103698-10-8 methyl 3-nitropyridine-4-carboxylate 

Downstream Products

• 316155-87-0 2-carboxy-(1,6)-naphthyridine 
• 316156-03-3 8-(4'-amino-biphenyl-4-ylmethyl)-5,6,7,8-tetrahydro-[1,7]naphthyridin-2-ylamine 
• 316155-95-0 2-tert-butoxycarbonylamino-8-(4-hydroxy-benzyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316156-07-7 2-amino-8-(4'-amino-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid tert-butyl ester 
• 316155-91-6 8-(4-benzyloxy-benzyl)-2-tert-butoxycarbonylamino-8H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316155-99-4 2-tert-butoxycarbonylamino-8-(4'-nitro-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 863785-91-5 2-phenyl-[1,7]naphthyridin-3-ol 
• 1352037-95-6 3-phenyl-2-(pyridin-4-yl)-1,7-naphthyridine 
• 1427555-50-7 ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate 
• 1427555-99-4 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid 
• 1427556-00-0 N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide 
• 1427588-51-9 4-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)-N-ethylpiperazine-1-carboxamide 
• 1334713-60-8 tert-butyl N-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)carbamate 
• 1427588-97-3 tert-butyl 4-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)piperazine-1-carboxylate 

Relevant articles and documents

BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is -NR3aC(O)-, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are indepndently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.

Synthesis of novel 1,7-naphthyridines by Friedlaender condensation of pyridine substrates

The general ability of appropriate pyridyl compounds (aldehyde or ketone) to undergo Friedlaender condensation to give different 1,7-naphthyridines has been demonstrated. 2,4-Disubstituted 1,7-naphthyridine 8 was prepared from 3-amino-4-acetylpyridine (6) and ketone 4 (82%). The Friedlaender self-condensation of pyridyl substrate 6 is reported, as well. The dimer product, 2-(3-aminopyridin-4-yl)-4-methyl-1,7-naphthyridine (7), was obtained in 97% yield. 2-Aryl-and 2,3-diaryl-1,7-naphthyridines (16-18) were prepared from 3-aminoisonicotinaldehyde (13) and arylketones 4, 14, and 15 (28-71%). The key substrates 6 and 13 are readily available via the improved pyridine nitration method. Copyright

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.